Cethromycin trade name Restanza (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax and was given an orphan drug status for this indication. Originally discovered and developed by Abbott it was acquired by Advanced Life Sciences Inc.
This page contains content from the copyrighted Wikipedia article "Cethromycin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.